Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.36 |
| ▸ | PLA2G4A | P47712 | 1/20 | 0.36 |
| ▸ | TLR7 | Q9NYK1 | 1/20 | 0.34 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.33 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.33 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.33 |
| ▸ | ACHE | P22303 | 1/20 | 0.33 |
| ▸ | MMP1 | P03956 | 1/20 | 0.33 |
| ▸ | MMP2 | P08253 | 1/20 | 0.33 |
| ▸ | MMP9 | P14780 | 1/20 | 0.33 |
| ▸ | MMP13 | P45452 | 1/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.32 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.32 |
| ▸ | ADRB3 | P13945 | 1/20 | 0.32 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29437960 | 1.00 | L3MBTL1 (0.38) | L3MBTL1ALDH1A1PLA2G4ATLR7HDAC1 | |
| SCHEMBL14983987 | 0.89 | KDM1A (0.34) | ALDH1A1TLR7HDAC1HDAC8HDAC6 | |
| SCHEMBL19389074 | 0.85 | ABCB1 (0.39) | ALDH1A1TLR7HDAC1HDAC8HDAC6 | |
| SCHEMBL12879880 | 0.85 | ABCB1 (0.39) | ALDH1A1TLR7HDAC1HDAC8HDAC6 | |
| Hydrochloric Acid SCHEMBL28631038 | 0.84 | ABCB1 (0.38) | ALDH1A1TLR7HDAC1HDAC8HDAC6 | |
| Hydrochloric Acid SCHEMBL28631036 | 0.84 | ABCB1 (0.38) | ALDH1A1TLR7HDAC1HDAC8HDAC6 | |
| SCHEMBL10042788 | 0.83 | RAB9A (0.52) | ALDH1A1KDM4EABCB1 | |
| Hydrochloric Acid SCHEMBL20529544 | 0.82 | RAB9A (0.54) | ALDH1A1KDM4EABCB1 | |
| Hydrochloric Acid SCHEMBL20529546 | 0.82 | RAB9A (0.54) | ALDH1A1KDM4EABCB1 | |
| SCHEMBL9415797 | 0.79 | L3MBTL1 (0.44) | L3MBTL1ALDH1A1PLA2G4ATLR7HDAC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 85 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230002440-A1 | ALTERNATIVE PROCESSES FOR THE PREPARATION OF TUBULYSINS AND INTERMEDIATES THEREOF | SEATTLE GENETICS, INC. (US) | 2023-01-05 | — | — | US | claimed |
| US-20220323601-A1 | PROCESS FOR THE PREPARATION OF TUBULYSINS AND INTERMEDIATES THEREOF | SEAGEN INC (US) | 2022-10-13 | — | — | US | claimed |
| US-11389543-B2 | Process for the preparation of tubulysins and intermediates thereof | SEAGEN INC. (US) | 2022-07-19 | — | — | US | claimed |
| US-20260091081-A1 | A FORMULATION OF A CONJUGATE OF A TUBULYSIN ANALOG TO A CELL-BINDING MOLECULE | HANGZHOU DAC BIOTECH CO., LTD (CN) | 2026-04-02 | — | — | US | disclosed |
| US-12576124-B2 | Formulation of a conjugate of a tubulysin analog to a cell-binding molecule | HANGZHOU DAC BIOTECH CO., LTD (CN) | 2026-03-17 | — | — | US | disclosed |
| US-20260048157-A1 | FIBROBLAST ACTIVATION PROTEIN (FAP)-TARGETED IMAGING AND THERAPY | PURDUE RESEARCH FOUNDATION (US) | 2026-02-19 | — | — | US | disclosed |
| EP-4696714-A1 | PREPARATION METHOD FOR NANOBODY TARGETING TISSUE FACTOR AND CONJUGATE AND USE THEREOF | Fudan University (CN) | 2026-02-18 | — | — | EP | disclosed |
| US-12508319-B2 | Luteinizing hormone-releasing hormone receptor (LHRH-R) conjugates and uses thereof | PURDUE RESEARCH FOUNDATION (US) | 2025-12-30 | — | — | US | disclosed |
| US-20250382376-A1 | NANOBODY AND NANOBODY-DRUG CONJUGATE TARGETING CD73, METHOD FOR PREPARING SAME, AND USE THEREOF | UNIV FUDAN (CN) | 2025-12-18 | — | — | US | disclosed |
| US-12419963-B2 | Diels-Alder conjugation methods | REGENERON PHARMACEUTICALS, INC. (US) | 2025-09-23 | — | — | US | disclosed |
| US-12397069-B2 | Fibroblast activation protein (FAP)-targeted imaging and therapy | PURDUE RESEARCH FOUNDATION (US) | 2025-08-26 | — | — | US | disclosed |
| US-11389543-B2 | Process for the preparation of tubulysins and intermediates thereof | SEAGEN INC. (US) | 2022-07-19 | — | — | US | disclosed |
| US-20220175947-A1 | CYSTEINE MUTATED ANTIBODIES FOR CONJUGATION | SEAGEN INC. (US) | 2022-06-09 | — | — | US | disclosed |
| EP-3986476-A1 | A FORMULATION OF A CONJUGATE OF A TUBULYSIN ANALOG TO A CELL-BINDING MOLECULE | Hangzhou Dac Biotech Co., Ltd. (CN) | 2022-04-27 | — | — | EP | disclosed |
| US-20220105208-A1 | FIBROBLAST ACTIVATION PROTEIN (FAP)-TARGETED IMAGING AND THERAPY | PURDUE RESEARCH FOUNDATION | 2022-04-07 | — | — | US | disclosed |
| EP-3546448-B1 | DI-SUBSTITUTED MALEIC AMIDE LINKER FOR ANTIBODY-DRUG CONJUGATING AND PREPARATION METHOD AND USE THEREOF | MABWELL SHANGHAI BIOSCIENCE CO LTD (CN) | 2022-04-06 | — | — | EP | disclosed |
| EP-3383420-B1 | CONJUGATES OF QUATERNIZED TUBULYSIN COMPOUNDS | SEAGEN INC (US) | 2022-03-23 | — | — | EP | disclosed |
| US-11274124-B2 | Tubulysin analogues as anticancer agents and payloads for antibody-drug conjugates and methods of treatment therewith | WILLIAM MARSH RICE UNIVERSITY (US) | 2022-03-15 | — | — | US | disclosed |
| WO-2022046941-A1 | ANTIMITOTIC TETRAPEPTIDE-ANTIBODY CONJUGATES AND METHODS OF USING SAME | ANGIEX, INC. (US) | 2022-03-03 | — | — | WO | disclosed |
| US-20220056079-A1 | THIRD GENERATION TUBULYSIN ANALOGUES AND PROCESS OF PREPARATION THEREOF | Indian Institute of Technology Indore (IN) | 2022-02-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (14 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220175947-A1 | CYSTEINE MUTATED ANTIBODIES FOR CONJUGATION | GCLC, CBS, CARS1 | L3MBTL1 100/4885ALDH1A1 1973/4885PLA2G4A 4190/4885 |
| US-20220323601-A1 | PROCESS FOR THE PREPARATION OF TUBULYSINS AND INTERMEDIATES THEREOF | VIP, TMPRSS15, TEKT1 | L3MBTL1 4801/4885ALDH1A1 4817/4885PLA2G4A 3327/4885 |
| US-12576124-B2 | Formulation of a conjugate of a tubulysin analog to a cell-binding molecule | CD4, TAP1, MCTS1 | L3MBTL1 241/4885ALDH1A1 4592/4885PLA2G4A 3764/4885 |
| US-12508319-B2 | Luteinizing hormone-releasing hormone receptor (LHRH-R) conjugates and uses thereof | LHCGR, GNRHR, SSTR1 | L3MBTL1 988/4885ALDH1A1 1775/4885PLA2G4A 3907/4885 |
| US-20250382376-A1 | NANOBODY AND NANOBODY-DRUG CONJUGATE TARGETING CD73, METHOD FOR PREPARING SAME, AND USE THEREOF | ENTPD1, ENTPD5, NT5E | L3MBTL1 4438/4885ALDH1A1 1744/4885PLA2G4A 905/4885 |
| US-20260048157-A1 | FIBROBLAST ACTIVATION PROTEIN (FAP)-TARGETED IMAGING AND THERAPY | FAP, FIBP, FGFR1 | L3MBTL1 3700/4885ALDH1A1 1412/4885PLA2G4A 1353/4885 |
| US-20260091081-A1 | A FORMULATION OF A CONJUGATE OF A TUBULYSIN ANALOG TO A CELL-BINDING MOLECULE | CD4, MALT1, LY6K | L3MBTL1 1568/4885ALDH1A1 4331/4885PLA2G4A 3077/4885 |
| US-20220056079-A1 | THIRD GENERATION TUBULYSIN ANALOGUES AND PROCESS OF PREPARATION THEREOF | TEK, VIP, SCTR | L3MBTL1 4150/4885ALDH1A1 4849/4885PLA2G4A 760/4885 |
| US-20230002440-A1 | ALTERNATIVE PROCESSES FOR THE PREPARATION OF TUBULYSINS AND INTERMEDIATES THEREOF | TMPRSS15, VIP, TEKT1 | L3MBTL1 4841/4885ALDH1A1 4570/4885PLA2G4A 3061/4885 |
| US-20220105208-A1 | FIBROBLAST ACTIVATION PROTEIN (FAP)-TARGETED IMAGING AND THERAPY | FAP, FIBP, FRS2 | L3MBTL1 3795/4885ALDH1A1 1776/4885PLA2G4A 541/4885 |
| US-12397069-B2 | Fibroblast activation protein (FAP)-targeted imaging and therapy | FAP, FIBP, FRS2 | L3MBTL1 3795/4885ALDH1A1 1776/4885PLA2G4A 541/4885 |
| US-11274124-B2 | Tubulysin analogues as anticancer agents and payloads for antibody-drug conjugates and methods of treatment therewith | TEK, CD2BP2, SDCBP | L3MBTL1 4429/4885ALDH1A1 3809/4885PLA2G4A 1277/4885 |
| US-12419963-B2 | Diels-Alder conjugation methods | GLUL, TGM2, GLS | L3MBTL1 1138/4885ALDH1A1 74/4885PLA2G4A 1375/4885 |
| US-11389543-B2 | Process for the preparation of tubulysins and intermediates thereof | VIP, TMPRSS15, TEKT1 | L3MBTL1 4801/4885ALDH1A1 4817/4885PLA2G4A 3327/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.